Based on a phase 3 clinical trial, gilteritinib was recently approved by the Pharmaceuticals and Medical Devices Agency and FDA as monotherapy for patients with relapsed/refractory FLT3-mutated AML [18]. Here, FLT3 is linked to acute myeloid leukemia.